Abstract | Up to a fifth of patients with colorectal cancer (CRC) present with synchronous hepatic metastases. In patients with CRC who present without intestinal obstruction or perforation and in whom comprehensive whole-body imaging confirms the absence of extrahepatic disease, evidence indicates a state of equipoise between several different management pathways, none of which has demonstrated superiority. Neoadjuvant systemic chemotherapy is advocated by current guidelines, but must be integrated with surgical management in order to remove the primary tumour and liver metastatic burden. Surgery for CRC with synchronous liver metastases can take a number of forms: the 'classic' approach, involving initial colorectal resection, interval chemotherapy and liver resection as the final step; simultaneous removal of the liver and bowel tumours with neoadjuvant or adjuvant chemotherapy; or a 'liver-first' approach (before or after systemic chemotherapy) with removal of the colorectal tumour as the final procedure. In patients with rectal primary tumours, the liver-first approach can potentially avoid rectal surgery in patients with a complete response to chemoradiotherapy. We overview the importance of precise nomenclature, the influence of clinical presentation on treatment options, and the need for accurate, up-to-date surgical terminology, staging tests and contemporary management options in CRC and synchronous hepatic metastatic disease, with an emphasis on multidisciplinary care.
Introduction
Colorectal cancer (CRC) is the third most common cancer in the USA. 1 Similarly, in Europe, CRC was the third most common form of cancer and cause of cancer-related death in 2012. 2 Metastasis often occurs in patients with CRC, and the liver is the site most frequently involved: 14-20% of patients have hepatic metastases at presentation, and up to a further third of patients initially diagnosed with a localized bowel cancer will subsequently develop liver lesions. 3, 4 Liver metastases in patients with CRC represents stage IV disease, in which 5-year survival is only 6%; 5 however, stage IV CRC encompasses a wide clinical spectrum of disease, and those patients with surgically resectable metastatic lesions confined to the liver have a 5-year survival rate of 25-40%. 5 Such patients represent a select, but important subgroup, in which long-term survival of up to 17% at 10-years has been reported after the hepatic metastatic burden is surgically removed. 6 Patients who present with metastatic liver disease after treatment of the primary CRC (termed metachronous disease) receive care focused on treating the new metastatic disease. 7, 8 By contrast, the management of patients who present with CRC and concurrent liver metastases (termed synchronous metastasis) is more complex. 8, 9 These patients can have less-favourable cancer biology and thus might have a reduced likelihood of long-term survival than those with metachronous liver involvement. 10 Logically, the management of patients with CRC and synchronous metastases can be dichotomised according to whether the patient has hepatic plus extrahepatic or liver-limited metastatic disease. Among indivi duals in the first category, systemic chemo therapy is the mainstay of treatment advocated in current guidelines for advanced-stage multisite metastatic (liver and systemic metastases) disease of CRC origin. 8, 11 However, the second category of patients with liverlimited synchro nous metastases represents a complex and common clinical management problem. 12 Traditional management of CRC with synchronous liver-limited metastasis, commonly referred to as the 'classic' or 'staged' approach, comprises resection of the colorectal primary tumour followed by interval chemo therapy, with liver resection being undertaken as a subsequent surgery. 13, 14 Advances in surgery, anaesthesia, critical care and chemotherapy have made two alternative treatment options feasible for patients with synchronous CRC and liver-limited disease. The first option is concurrent resection of the liver metastases and the colorectal primary tumour. 12, 14 This approach is attractive as the macroscopic tumour burden can be removed during a single operation; however, the morbid ity associated with complex liver resection combined with major bowel resection can be considerable, 15 and some evidence indicates that simultaneous resection might have a negative effect on progression-free survival (PFS) compared with classic delayed hepatectomy.
14 de Haas and colleagues reported that 3-year overall survival and PFS rates were 74% and 8%, respectively, in the synchro nous surgery cohort compared with 70% and 26%, respectively, in the staged surgery group, with the difference in PFS of staged patients reaching statistical significance (P = 0.005). 14 The second alternative to the classic bowel-first surgical approach to the management of synchronous CRC and liver-limited disease is resection of the liver metastatic disease as the first step, termed the 'reverse' or 'liver-first' approach. 16, 17 Liver-first surgery to manage synchronous CRC and liver metastases has become more widely used owing to a number of oncological and technical developments. The classic approach of surgical resection of rectal tumours as the first step has been superseded in selected cases by preoperative chemo radiotherapy, which can be undertaken after neoadjuvant systemic chemotherapy and liver resection. 18 In addition, the technical development of colonic stenting permits symptoms associated with rectosigmoid cancer, such as partial obstruction of the colon, to be palliated without resorting to urgent bowel surgery. 19 The liverfirst strategy might be advantageous if liver metastatic disease rather than the primary cancer gives rise to systemic metastasis, although whether liver metastases drive systemic spread has not been established. 20 A further potentially important benefit of the liver-first approach is that, in selected patients with rectal tumours with a complete endoscopic, radiological and clinical response to chemoradiotherapy, pelvic surgery can be less e xtensive or avoided altogether. 21 This Review addresses the management of patients with CRC with synchronous hepatic metastases and examines relevant aspects of current terminology, the influence of the mode of clinical presentation on the management strategy used, diagnostic and staging tests and the key issues regarding the options for integration of surgical management into oncological care. The importance of involvement of modern multidisciplinary teams in the planning of treatment is emphasized, with the goal being to provide a synthesis of evidence that supports an holistic, personalized treatment approach.
Current terminology
In current colorectal clinical practice, the terms 'synchronous liver metastasis' or 'synchronous liver metastases' refer to the presence of hepatic lesions arising from a colorectal primary tumour that are evident at the time of clinical presentation or detected with the colorectal tumour. 22 Conversely, the term 'metachronous metastasis' is used to describe lesions presenting at a later time point than that at which the primary CRC is diagnosed. 23 However, no clear consensus has been reached regarding the definition and usage of the term 'synchronous' and, therefore, 'metachronous' . For example, the current American Joint Committee on Cancer (AJCC) manual 24 states that staging of synchronous disease can be undertaken up to 4 months after detection of the primary tumour, whereas Mekenkamp et al. 25 reported the clinicopathological features and outcome of synchronous colorectal metastases defined as distant lesions occurring within 6 months of the primary diagnosis of the CRC. Precise use of disease descriptors is required to enable comparison of reported data. For instance, before the term metachronous metastases is used to define hepatic lesions, adequate imaging of the liver at the time of index presentation of the colorectal primary tumour should be performed to ensure that synchronous lesions are not misclassified.
In addition to the lack of clinical clarity and potential overlap in the usage of these definitions related to nomenclature, synchronous and metachronous metasta ses cannot be clearly distinguished based on current understanding of the cancer biology of these hepatic lesions. 26, 27 Current knowledge of the molecular biology of CRC does not preclude patients with apparent metachronous metastases having clinically occult synchronous micrometastatic hepatic lesions at the time of presentation of the primary tumour, which only become clinically a pparent at a later stage. 28, 29 Thus, to standardize future reporting of information, we suggest that the following pragmatic definitions of synchronous and metachronous hepatic lesions should be exclusively used in the context of CRC-associated liver metastasis. Synchronous hepatic metastases of colorectal origin should be defined as liver lesions with the radiological imaging characteristics-on cross-sectional imaging comprising any of CT, MRI or 18 F-deoxyglucose PET ( 18 FDG-PET)-of colorectal liver metastases that are present either at the time of detection of the primary CRC or detected within 6 months of CRC presentation; liver metastases identified at the time of index colo rectal surgery should also be considered synchronous. Correspondingly, metachronous hepatic metastases are defined as liver lesions with radiological imaging character istics consistent with colorectal origin that are detected >6 months after presentation of the primary bowel tumour, providing that adequate cross-sectional imaging of the liver was performed in the preceding time period. This last caveat is important in making the distinction between patients who present with late-declared metastases and those in whom synchronous metastases have not been detected because of limited or inadequate staging. More stringent criteria than those we suggest would define synchronous disease Key points ■ Up to a 20% of patients with colorectal cancer (CRC) present with synchronous hepatic metastases ■ In patients who present without intestinal obstruction or perforation, comprehensive whole-body imaging is required to exclude extrahepatic disease ■ Current evidence indicates a state of equipoise between several different management approaches for the treatment of CRC and synchronous liver metastatic disease, none of which has supportive randomized trial evidence ■ Neoadjuvant systemic chemotherapy is supported by current guidelines and can result in tumour downsizing, enabling some 'unresectable' liver metastases to be surgically removed ■ Surgery can take the form of the 'classic' approach (colorectal resection, then interval chemotherapy followed by liver resection), synchronous removal of liver and bowel tumours, or a liver-first approach ■ Clear superiority has not been demonstrated for any of these surgical interventions for CRC with synchronous liver metastases, although the mode of presentation can determine the approach used as present at the time of initial clinical presentation, provided that adequate staging and imaging was performed, and thus any metastases detected at a later stage would be classified as metachronous, but the fact that these terms are not currently used with this degree of precision must be appreciated. Synchronous and metachronous metastases defined according to our proposed classification can be further divided into liver-limited hepatic lesions if adequate full-body cross-sectional imaging has confirmed that no radiologically detectable disease-apart from the primary tumour and the hepatic metastatic burden-is present, and systemic disease when disease is located beyond the liver and bowel, typically as lung but also p eritoneal and omental metastases. 30 
Influence of presentation on treatment
The clinical status of disease at presentation has a substantial influence on the practical aspects of subsequent treatment. 31, 32 Logically, the mode of presentation can be divided into asymptomatic and symptomatic categories, with the latter being further dichotomized for treatment planning into urgent and non-urgent manifestations. 32, 33 Asymptomatic patients with hepatic metastases can be detected in CRC screening programmes. 34, 35 Indeed, a report of the first 1 million people enrolled in a UK CRC screening programme-where screening is offered to adults aged 60-69 years based on positive faecal occult blood tests-showed that approximately 3% of the 17,518 individuals with positive faecal occult blood tests who were further investigated had stage IV disease involving the liver. 36 Another important group of patients with liver metastases are those who present with cancer of unknown primary (CUP). 37, 38 These patients can lack specific CRC symptoms, but often demonstrate general nonspecific features of advanced malignancy such as nausea, weight loss and malaise. True CUP comprises about 3-5% of all cancer diagnoses and is most common in older individuals (aged >50 years). 39 Liver lesions resulting from a clinically occult primary cancer are typically adenocarcinomas in most patients with CUP and, therefore, the most probable location of the primary source of cancerous cells include the breast, colon, prostate, stomach, pancreas and lung. 39 In most patients with CUP, liver metastases are present in conjunction with disease at other sites. 39 The performance status of the patient has an important influence on their management when presenting with liver metastases without a known primary tumour, as this factor determines the extent of further investigation and subsequent treatment. If a solitary liver lesion presents as CUP in a patient with a relatively well-preserved performance status, endoscopic assessments of the upper and lower gastrointestinal tract in an attempt to locate the primary tumour represent the logical next series of investigations, with biopsy of the liver being avoided. By contrast, in frail patients with poor performance status and bilobar liver metastases, and without gastro intestinal symptoms, percutaneous ultrasonography-guided or CT-guided biopsy of the hepatic lesion(s) could help to establish the diagnosis.
In patients who present with symptomatic CRC, the nature of the symptoms has a profound influence on the staging and neoadjuvant treatment modalities used. For example, patients who present with peritonitis resulting from a bowel perforation caused by colon cancer require treatment directed at resuscitation and salvage surgery, regardless of the presence of liver metastases. 40 In this setting, limited or no preoperative staging of the bowel tumour, no neoadjuvant chemotherapy and no staging or intervention directed at the liver metastases is possible. 40 In general, CRCs presenting as clinical emergency have a more-aggressive histopathological profile and a more-advanced stage than those detected under other circumstances. 41 Traditionally, patients presenting with left-sided obstructing CRC and synchronous liver-limited metastases required urgent surgery directed at relieving the obstruction. 40 Such urgent surgery can take the form of defunctioning stoma without resection of the primary tumour or resection of left-sided obstructing lesion with end-colostomy. 42, 43 However, the advent of colonic stenting has provided a nonsurgical option for relief of intestinal obstruction in patients with CRC. 44, 45 If the obstruction can be relieved by placement of a colonic stent, emergency surgery can be avoided, and the various approaches that might enable more-accurate staging and more-appropriate treatment of the disease can be evaluated; 45 therefore, better morbidity and mortality outcomes might be achieved. Once completed, the ongoing Cancer Research UK study, CReST, 46 will provide a random ized comparison of endoluminal colonic stenting and emergency surgery in the treatment of obstructing left-sided CRC, although this study is not designed to specifically address the management of patients with synchronous liver metastases as a discrete cohort. As success ful stent placement enables patients with obstructing CRC with synchronous liverlimited metastases to be managed similarly to those with non-obstructing disease, the morbidity and mortality data from the CReST trial could nevertheless prove i nformative in this setting.
Staging of liver metastases
Radiological assessment and staging Cross-sectional imaging by CT or MRI forms the foundation for detection of hepatic metastases derived from a primary CRC. 47 The current North American National Comprehensive Cancer Network (NCCN) guidelines for the initial staging of CRC suggest the use of CT or MRI of the chest, abdomen and pelvis, with 18 FDG-PET-CT imaging reserved for situations in which curative resection is being considered. 48 The value of comparing the available data on the diagnostic sensitivities and specificities for the detection of liver lesions using these various modalities is relatively limited, as the studies performed to date used a range of different scanning protocols, scanners with different image resolution properties and consensus regarding the 'gold-standard' comparator was lacking. [49] [50] [51] [52] Furthermore, the imaging assessments are complementary and not necessarily mutually exclusive.
Contrast-enhanced CT is used widely as the first cross-sectional imaging assessment in patients with CRC and should include views of the thorax and pelvis. Image acquisition should be performed before the use of any neoadjuvant chemotherapy to determine the pretreatment baseline distribution and extent of disease within the liver. In addition, liver MRI can provide an accurate 'road map' of the anatomical distribution of lesions, helps to distinguish metastases from benign lesions and can also provide information relating to surround ing liver parenchyma (such as the development of post-chemotherapy steatohepatosis). 47 Technical advances in MRI include the use of liver-specific contrast agents-such as gadolinium-that are taken up by hepatocytes but not by metastatic tissue, 52 and diffusion-weighted imaging protocols, which enables analysis of differences in the diffusion of intravenously administered contrast agent between normal liver parenchyma and tumour-bearing liver. 53 Nevertheless, MRI scanners are not suitable for patients who complain of claustrophobia, have implanted metal devices 47 or are at risk of nephrogenic systemic fibrosis (NSF) associated with the use of gadolinium. 54 18 FDG-PET has an important role in the diagnostic and staging algorithm; current evidence-based indications for 18 FDG-PET in the UK recommend the use of this imaging modality in the staging of patients with synchronous CRC and metasta ses at presentation, before consideration of surgical resection. 55 The incorpor ation of 18 FDG-PET scanning into staging algorithms can facilitate detection of extrahepatic disease and, therefore, can reduce the need for nontherapeutic laparo tomy; 56, 57 however, false positives can result from uptake of 18 FDG in areas of increased metabolic activity owing to inflammation (for example, around healing intestinal anastomoses), and false negatives can be associ ated with mucinous primary colorectal adenocarcinoma and occasionally after c hemotherapy is performed a short time before imaging.
The general availability of ultrasonography makes this imaging modality useful in initial diagnostic testing in an outpatient setting. 58 Contrast-enhanced ultrasonography (CEUS) might also be useful as an adjunctive test for characterization of liver lesions. 59 In a detailed health-technology assessment, the pooled estimate of sensitivity for detection of any malignancy using CEUS was 95.1% and the corresponding specifi city estimate was 93.8%. 59 Importantly, the performance of CEUS is operator-dependent, and this approach does not provide the anatomical information on the relation ship between liver lesion and adjacent vascular structures that is necessary for planning liver-resection pro cedures. By contrast, intraoperative ultrasono graphy (IOUS) is a standard component of liver surgery for CRC-associated hepatic metastases and a systematic protocol of scanning all liver segments before resection helps to confirm the location of disease and to correlate intraoperative findings with data from pre operative imaging assessments. 60 When used in a systematic i ntraoperative protocol, IOUS can also detect additional small-volume lesions. 61 Biochemical assessment and staging The complex glycoprotein carcinoembryonic antigen (CEA) is used widely in post-resection surveillance. 62 Current UK guidelines for the management of patients with CRC hepatic metastases recommend that a baseline CEA assay is undertaken at patient presentation to serve as a comparator for post-resection surveillance. 62 In addition, analysis of data from the European Organisation for Research and Treatment of Cancer (EORTC) 40983 study of liver resection with or without neoadjuvant chemo therapy demonstrated that elevated preoperative blood CEA levels predicted subsequent response to chemo therapy. 63 Nevertheless, the utility of CEA as a predictor of response to chemotherapy remains to be more widely established.
Staging laparoscopy
Staging laparoscopy is widely used in the preoperative staging of patients with upper abdominal malignancy, as this procedure complements CT imaging by enabling the detection of small-volume liver-surface or peritoneal meta static disease that might not be identified using the latter approach. 64, 65 In the assessment of patients with CRC with known hepatic metastases, however, staging laparo scopy adds relatively limited additional value to cross-sectional imaging, creates a risk of procedurerelated visceral injury in patients who have previously undergone CRC resection and is, therefore, not routinely advocated. 66, 67 Dunne et al. 66 reported 12 nonresectional laparotomies in a series of 274 patients undergoing open hepatectomy in a no-laparoscopy protocol (4.4%), and unresectability was due to peritoneal carcinomatosis that could have been detected if staging laparoscopy had been used in five patients (1.8%). 66 
Assessment of fitness for surgery
Preoperative assessment of patient performance status and thus suitability for surgery comprises combinations of clinical examination, risk scores and other tests, such as pulmonary function testing, 68 echocardiography 69 and cardiac perfusion scans. 70 Liver surgery is increasingly offered to older patients with metastatic CRC and co existing co morbidity. Furthermore, the ability of a patient to tolerate liver resection might be compromised by prior chemotherapy. In these settings, thorough preoperative risk assessments are especially important. Cardiopulmonary exercise testing (CPET) provides a reliable, reproducible noninvasive test of dynamic cardiac and pulmonary function, and our group previously demon strated that a low anaerobic threshold is a useful predictor of postoperative outcome; 71 an anaerobic threshold below 9.9 ml O 2 /kg/min was associated with a 100% sensitivity and 76% specificity for prediction of in-hospital death with a positive predictive value of 19% and a negative predictive value of 100%. 71 No deaths occurred above this threshold in a cohort of 108 patients who underwent preoperative CPET before liver resection. 71 Although CPET is increasingly used in preoperative risk assessments, further independent validation of our f indings in patients undergoing liver resection is required before the w idespread adoption of this technique.
Definitions of liver resectability
Extent of liver resection Up to 70% of the normal adult human liver can be resected; 57 however, the amount of liver parenchyma that can be safely resected is compromised by host factors, such as age and coexistent disease (fatty-liver disease), and also by the delayed effects of systemic chemotherapy: oxaliplatin treatment is associated with sinusoidal obstruction producing a 'blue tinge' in the post-chemotherapy liver, 72 whereas exposure to irinotecan is associated with steatohepatitis. 73 Presently in liver surgical practice, important criteria in defining resectability include ensuring that hepatic portal and arterial inflow of blood to the neo remnant liver (with concomitant biliary drainage), together with hepatic venous outflow will be preserved after removal of the disease-bearing parenchyma ( Figure 1) . 74 In patients with synchronous disease in whom a simultaneous liver and bowel resection is planned, many surgeons prefer to undertake relatively minor liver resections in combination with a major colorectal resection. Although there is no consensus on what constitutes a 'minor' resection, this term would apply to some anatomical resections, such as left lateral sectionectomy (Figure 2) , and non-anatomical metastasectomy procedures. In turn, major liver resection is more often undertaken in combination with a relatively minor right-sided colon resection. Currently, however, insufficient evidence is available to guide the precise extent of liver resection that can be safely undertaken in combination with colorectal resection.
Liver-resection nomenclature Part of the difficulty in understanding the safe extent of liver resection arises from nonstandard terminology used throughout the literature. Increasing acceptance of the terminology proposed at the 2000 Brisbane consensus conference 75 ( Figure 1 ) will help to standardize description of liver resection across studies. In brief, sections of the liver are anatomically discrete, each having dedicated hepatic arterial and portal inflow and biliary drainage vessels (Figure 1 ). The right hemi-liver can be sub divided into an anterior section (comprising segments 5 and 8) and a posterior section (comprising segments 6 and 7), with these sections separated by the right hepatic vein. The left hemi-liver has a lateral section (segments 2 and 3) and a medial section (segment 4). With regard to anatomical resection of the liver, classic surgical right hemi-hepatectomy (removal of the right anterior and posterior sections) can be referred to as a right bisectionectomy according to this termino logy ( Figure 2) . 75 Although perhaps slightly cumbersome, such terms are clear, anatomically accurate and, most importantly, permit c omparison across reports.
Disease management
CRC with beyond-liver systemic metastasis Systemic chemotherapy is the mainstay of care for patients with advanced CRC-that is, 'beyond-liver' systemic metastatic disease-in whom performance status is sufficient to permit treatment. 8 Although liver lesions in such individuals are typically asymptomatic, bowel symptoms are often evident and thus intervention to relieve intestinal obstruction might be required as a first step of treatment. For those with obstructing left-sided cancers, it can be possible to achieve this outcome by removing the obstruction through endoscopic stenting. 19 The European Society of Medical Oncology (ESMO) guidelines 8 consider systemic chemo therapy for patients with advanced CRC in two clinical scenari os: firstly, for neoadjuvant or palliative treatment of patients who might become candidates for liver resection following chemotherapy to downsize the tumour; and secondly, for systemic treatment of patients who will never be candi dates for surgery either owing to the location of the disease or involvement of multiple sites (Figure 3) . 8 In the latter context, liver resection is not recommended in patients with unresectable, locally advanced primary CRC tumours, 76 peritoneal metastatic disease, 77 nodal involvement of the liver hilus 78 or pulmonary metastatic disease. 79 For patients with disease that will never be resectable, an holistic approach based on palliation of symptoms and optimization of quality of life is important. Although reports have highlighted select circumstances in which aggressive surgery after chemotherapy could be of potential benefit, the efficacy of this approach is not supported by good-quality r andomized trial e vidence for any of these scenarios. [76] [77] [78] [79] CRC with metastasis to the lung and liver only Limmer and colleagues 80 reported a series of 1,497 patients with primary CRC treated using surgical resection over an 18-year period. Of these individuals, 73 developed both hepatic and pulmonary metastases and 17 of these patients underwent synchronous liver and lung resection. 80 The 3-year, 5-year and 10-year survival rates after liver and lung resection among patients with both hepatic and pulmonary metastases were 77%, 55% and 18%, respectively. 80 Clearly, these patients represent a highly selected series and resection of lung metastases derived from CRC remains controversial. 79 A national registry of lung resection surgery for CRC pulmonary metastases was established by the Grupo Español de Cirugía Metástasis Pulmonaires de Carcinoma Colo-rectal (GECMP-CCR) and data have been reported for 543 patients undergoing pulmonary metastasectomy (for one or more pulmonary nodules). 81 The majority of these patients (n = 293 [55%]) underwent pulmonary metastasectomy for a solitary lung metastasis presenting at a median interval of 28 (interquartile range 16-43) months after primary bowel-cancer resection. 81 45 patients (8.3%) had liver metastases at the time of pulmo nary metastasectomy, and liver and lung metastases were treated at the same time in 7.7% of patients included in this registry. 81 Key features indicating a good prognosis were the presence of a solitary lung metastasis and an interval of more than 3 years between presentation of the primary tumour and the lung lesion. 81 Overall, the presence of both liver and lung metastases was not associated with a favourable prognosis. 81 Longer-term outcome data from this registry might clarify the role of pulmonary resection in the treatment of CRC with both liver and lung metastases, and such data are awaited.
According to current guidelines, 8, 11 lung metastases presenting with synchronous CRC liver metastases would be categorized as systemic disease and systemic chemotherapy would be recommended. No randomized trial evidence supports the practice of lung resection in patients with CRC with synchronous hepatic metastatic disease, although a survey of thoracic surgical practice in the UK-a questionnaire sent to members of the Society for Cardiothoracic Surgery in Great Britain and Ireland-revealed evidence of considerable variation in the use of lung surgery in clinical practice. 82 Specifically, although a solitary lung metastasis was the most frequent indication for surgery, 59 (88%) of respondents did not consider lung lesions in the presence of liver metastases to be contraindications to surgery. To address this issue, PulMiCC, 83 a randomized trial of pulmonary metastasectomy versus active monitoring in patients with CRC, is being undertaken in 11 centres in the UK. In summary, pulmonary metastasectomy in patients with CRC and synchronous hepatic metastases must be considered with caution, and current opinion favours regarding these patients as having systemic disease and treating them accordingly.
CRC with synchronous liver-limited metastases
The contemporary management of patients with CRC with liver-limited metastatic disease relies on optimal disease staging, awareness of the influence of the mode of presentation on available treatments, and an integrated oncological and surgical approach. In practical terms, treatment planning decisions should involve a multi disciplinary cancer-care team. In the UK, current National Institute for Health and Care Excellence (NICE) recommendations 11 are that all patients with liver-limited hepatic metastases of colorectal origin should have their care reviewed and an index treatment plan formulated at an appropriately constituted regional hepatopancreatobiliary (HPB) multidisciplinary cancer-care team. Key members of such a multidisciplinary team include medical and clinical oncologists, liver and colorectal surgeons, radiologists with expertise in cross-sectional imaging, experts in nuclear medicine, histopathologists, and specialist cancer nurses and dieticians. It is important that treatment planning decisions are communicated effectively and promptly to patients, and that patients have the choice of retaining a permanent record of consultation and are made aware of the range of potential treatment options, as well as the evidence available for each approach. 11 
Synchronous or sequential resection?
A synchronous surgical approach can be used when liver resection can be combined with a colon resection that does not involve extensive pelvic dissection. 84 Recognizing the limited evidence available to guide decision-making, Pathak et al. 84 suggested a practical approach based on the nature of the surgery required. For example, patients requiring a straightforward primary tumour resection and liver resection procedure should undergo synchronous resection (Figure 3) . 84 Whereas, an easily resectable primary tumour combined with borderline resectable or unresectable liver tumours necessitates chemotherapy followed by hepatectomy, with subsequent resection of the primary tumour. 84 Conversely, in patients with difficult-to-resect or unresectable primary tumours with hepatic metastases requiring an easy liver resection surgery, chemotherapy should be used to treat the primary tumour (chemoradiotherapy for a rectal lesion) before primary tumour resection, followed by a hepatectomy. 84 Limitations of these recommendations include the lack of definition of what constitutes a 'straightforward' liver resection, the relative lack of priority allocated to systemic chemotherapy and the absence of an evidence base to guide any of these options.
In planning for synchronous resection, the probable location of any future stoma that might be necessary should be given due consideration, and a long midline incision with a right transverse extension might provide optimal access; left-sided liver tumours can usually be accessed via a midline incision only, avoiding the right transverse extension. In addition, a completely l aparoscopic approach-l aparoscopic colectomy plus laparo scopic hepatectomy-has been reported in small series of highly selected patients; 85 however, this approach requires further investigation.
Neoadjuvant chemotherapy in resectable disease
The EORTC Intergroup trial 40983 86 was a randomized comparison of perioperative chemotherapy using the FOLFOX4 regimen (folinic acid, 5-fluorouracil and oxaliplatin)-administered as six fortnightly cycles of chemotherapy before liver surgery and six cycles after hepatectomy-with liver resection alone in patients with up to four liver metastases classified as resectable at baseline assessment; 128 patients (35%) in this study had synchronous disease. 86 Although outcome was not reported separately for the patient subgroup with synchronous disease, the overall results revealed an absolute increase in the rate of PFS at 3 years of 7.3% (from 28.1% [95% CI 21.3-35.5] to 35.4% [95% CI 28.1-42.7]; HR 0.79, 95% CI 0.6-1.0; P = 0.058) in the patients randomized to receive neoadjuvant chemotherapy. 86 However, reversible postoperative complications occurred more often in the chemotherapy cohort than the surgery alone cohort (40/159 [25%] versus 27/170 [16%]; P = 0.04). 86 Of note, the absolute differences in outcomes observed between the two cohorts in this study were small and the survival curves follow apparently convergent paths. 86 Furthermore, a long-term follow-up report of this trial showed no differ ence in survival between groups. 87 Nonetheless, the Figure 3 | Flowchart outlining the management of CRC with synchronous liver metastases (modified based on ESMO guidelines). 8 The flowchart refers to the recommended management of patients with CRC with liver-limited hepatic metastases. The term 'intensive chemotherapy' is used to describe systemic chemotherapy for ≥6 months. There is no recommendation in relation to synchronous or staged resection. Abbreviations: CRC, colorectal cancer; ESMO, European Society for Medical Oncology; FOLFOX, folinic acid, 5-fluorouracil and oxaliplatin; HPB, hepatopancreato biliary.
landmark EORTC 40983 study established two important points: first, up to 3 months of neoadjuvant chemotherapy is feasible in patients with synchronous CRC and liver metastases; second, major liver resection involving 'p lurisegmentectomy'-resection of multiple liver s egments-is feasible in patients who have received systemic chemotherapy, as 86 of patients in the chemotherapy arm (57%) underwent such surgery. 86 Moreover, important lessons can be learnt from EORTC 40983 trial, including the need for better definition of the nature and extent of liver surgery; for instance, plurisegmentectomy is not a widely recognized term and could potentially encompass a series of small resections of nonadjacent liver segments or a single larger liver resection. Widespread adoption of consensus terminology, such as that proposed at the 2000 Brisbane conference (Figure 1; Figure 2) , 75 would improve standardization of reporting and thus strengthen the evidence base. In a systematic review of 3,278 patients with CRC hepatic metastases treated with neoadjuvant chemo therapy in a range of trials and using a broad range of chemotherapy agents, Chua et al. 88 reported that an objective (complete or partial) radiological response was observed in two-thirds of patients. These data add to the evidence support ing neoadjuvant systemic chemotherapy in patients with CRC with synchronous liver metastases.
In addition, attempts have been made to integrate treatment with biological agents into the neoadjuvant chemotherapy protocol. 89 In particular, cetuximab, a chimer ic monoclonal antibody targeting the EGFR, 90 might have therapeutic potential in this setting, as the EGF pathway involving RAS is an important component of cell prolifer ation, apoptosis and tumour-induced neoangiogenesis. 91 However, activating mutations in the KRAS oncogene that can result in EGFR-independent and thus cetuximab-resistant constitutive activation of the RAS signalling pathway are found in 35-40% of patients with metastatic CRC, 90 who would, therefore, not be eligible for such treatment. Hence, in the New EPOC portfolio study performed by the UK National Cancer Research Network, 89 the addition of cetuximab in a neoadjuvant setting was evaluated in patients with CRC with wild-type KRAS and resectable liver metastases. Preliminary results of the New EPOC study were presented at the 2013 ASCO meeting, 89 and showed that, contrary to expectation, neoadjuvant cetuxi mab therapy combined with conventional oxaliplatin-fluropyrimidine chemotherapy was associated with a worse outcome than oxaliplatin-fluropyrimidinebased chemotherapy alone (PFS of 14.8 months versus 24.2 months; HR 1.50, 95% CI 1.00-2.25; P <0.048). The full implications of these findings remain to be assessed; however, this result highlights that the interaction between systemic chemotherapy and biological treatments is complex and is an area currently under investigation.
Downsizing initially unresectable metastases
Patients with CRC and liver metastases might be unsuitable candidates for surgery because of extrahepatic disease. The extent and distribution of the disease burden within the liver can also render the liver metastases unresectable, although in this setting chemotherapy can be used in an attempt to downsize the liver metastases and improve the feasibility of resection. Adam et al. 92 investigated this approach in a large series of patients with initially unresectable disease treated by systemic chemotherapy with 'downstaging' intent. Among 1,439 consecutive patients with CRC hepatic metastases managed at a single centre over an 11-year period (1988-1999), 1,104 patients with initially unresectable disease were treated by chemotherapy in this study and 335 patients with resectable disease underwent primary liver resection.
92 138 (12.5%) of the 1,104 patients with liver lesions that were initially considered unresectable subsequently underwent hepatic resection after an average of 10 cycles of chemotherapy, predominantly with FOLFOX regimens; 92 survival in this group was 33% and 23% at 5 years and 10 years, respectively. 92 Although these survival figures are lower than in those patients who were eligible for primary resection (among whom 5-year and 10-year survival was 48% and 30%, respectively), 92 the findings demonstrate the potential of this approach.
With regard to the choice of induction chemo therapy in patients with hepatic disease that might become resectable, a pooled analysis of 29 studies (eight randomized controlled trials, one phase IV trial, two phase II trials, four observational studies, four prospective non randomized cohort studies and 10 retrospective case-series), comprising a total of 3,502 patients, has evaluated the 5-FU, folinic acid and irinotecan (FOLFIRI) plus bevacizumab (FOLFIRI-B) regimen; overall, the pooled response rate was 51.4%, median PFS was 10.8 months (95% CI 8.9-12.8) and median overall survival was 23.7 months (95% CI 18.1-31.6). 93 At present, however, a wide range of protocols are in use for downsizing, and thus clarification of the mostappropriate approach would be beneficial. Furthermore, the optimal duration of neoadjuvant chemotherapy is also currently unclear. Although Adam et al. 92 used up to 10 cycles of neoadjuvant chemotherapy in their protocol, Kishi and colleagues 94 reported that administration of nine cycles of neoadjuvant treatment was associated with increased hepatotoxicity without a corresponding increase in oncological response. In addition, the CELIM study, 95 a randomized comparison of FOLFOX6 plus cetuximab and FOLFIRI plus cetuximab in patients with liver-limited hepatic metastases defined as unresectable at inclusion, showed that, overall, inter vention resulted in 34% of patients subsequently achieving an R0 resection (38% and 30% from each cohort, respectively). Considering the aforementioned detrimental effect of cetuximab when combined with perioperative chemotherapy, 89 this finding adds to the current complexity regarding neoadjuvant chemotherapy.
The goal of surgery after downsizing of 'unresectable' hepatic metastases should be the removal of all areas of the liver in which lesions were identified (before chemotherapy). 96 When achieving this outcome is unlikely to be technically feasible because of known multisegment involvement and/or unfavourable location of metastasis before surgery, disease might be better regarded as 'never resectable' , rather than 'unresectable' . In practice, all such decisions, including the assessment of response to chemotherapy given with downsizing intent, require input from an experienced multidisciplinary team. 11 
Surgery for liver metastases
Nonanatomical versus anatomical resection Hepatic surgery for CRC liver metastases can take the form of metastasectomy, involving resection of the metastasis with a clear surrounding margin of normal liver parenchyma only. In single-centre clinical cohort studies, 97, 98 this type of 'nonanatomical' resection is not associated with a higher recurrence rate than formal 'anatomical' hepatectomy, in which larger defined sections of the liver are removed. Parenchyma-preserving liver surgery has the advantage of conserving liver tissue to enable repeat h epatectomy at a future date, should it be needed. 99 For resection of colorectal hepatic metastases, the princi pal operative goal, irrespective of the approach used, is to achieve a complete resection (R0; no residual disease). However, the importance of the resection margin in determining disease outcome is debated: although a 1 cm resection margin has been the conventional surgical goal, lesser distances between tumour and resection margin are also associated with low local-recurrence rates. 97 In a clinical cohort study in 2,715 patients undergoing liver resection for CRC hepatic metastases a ≥1 mm cancer-free resection margin was sufficient to achieve 33% 5-year overall disease-free survival (DFS). 97 Furthermore, wider resection margins did not significantly improve the DFS rates (P >0.05). 97 In fact, no significant difference in DFS was observed between patients with negative margins with narrow (1 mm) and wider clearance of the tumour margins (P = 0.579 and P = 0.149 using 5 mm and 10 mm as the wider cut-off, respectively).
Modification of the future remnant liver For complex and major liver resections, formal assessment of adequacy of the residual volume of liver in maintaining function capacity can be performed. 100 Clearance of indocyanine green dye is a test widely used for this purpose and other techniques include assessment of liver stiffness by transient elastography. 101 However, in relation to patients with synchronous CRC and liver metastases who have received neoadjuvant chemotherapy, evidence indicates that the rate of indocyanine green clearance does not correlate with the degree of chemotherapy-related hepatic sinusoidal injury. 102 Thus, care is needed when assessing post-resection liver function in such individuals.
Topographical anatomical assessment of the liver can be undertaken by CT volumetry. 103 If the future post operative remnant liver is predicted to be inadequate, the future liver remnant can be modified through percutaneous portal vein embolization (PVE). 104 This technique involves placement of either gel foam or coils into the portal vein to either the right or left hemi-livers under ultrasonographic guidance, resulting in occlusion of the blood vessel that subsequently leads to atrophy of the embolized side of the liver and hypertrophy of the contralateral side. 105 The rate of hypertrophy (kinetic growth rate) of the future remnant liver after PVE has been established as a predictor of post-resection outcome. 106 It should be noted, however, that reports have indicated that PVE is associated with an increased tumour growth rate in the remnant liver before resection. 107 Modification of the future remnant liver might also be possible to achieve operatively. Specifically, ligation of the right portal vein and in situ splitting of the liver promotes rapid hypertrophy of a previously inadequately sized left lobe. 108 This technique, known as ALPPS (associ ating liver partition with portal vein ligation for staged hepatectomy), is new, and as such its indicated use and riskto-benefit ratio remain undefined. At the present time, this procedure should be regarded as requiring more formal evaluation, in particular, to define indications, safety profile and outcomes of the technique. Indeed, no reported experiences are available that relate to the use of the ALPPS technique in patients with CRC with synchronous liver metastatic disease in whom the primary tumour remains in situ.
Two-stage hepatectomy
In patients with bilobar, liver-limited hepatic metastases (with or without hypertrophy after PVE), sequential two-stage hepatic resection is an option for removal of the liver disease. 109 The first-stage hepatectomy can be combined with the bowel resection. 110 In a small series of patients (n = 33) with synchronous disease treated using this method, 20 individuals (61%) received neoadjuvant chemotherapy and the initial surgical procedure undertaken was a left hepatectomy combined with bowel resection. 110 Of note, disease progression prevented completion hepatectomy in eight patients (24%), but among those who completed the protocol, overall survival and DFS rates were 48% and 22%, respectively, at 5 years. 110 These outcomes seem comparable to those observed after s ynchronous single-stage hepatectomy and bowel resection.
14 Nonresectional ablative treatments CRC liver metastases can be treated by ablation therapies instead of resection. 111 The most widely used ablative treatments use either radiofrequency (termed 'radiofrequency ablation' [RFA]) 112 or microwave energy sources. 113 Abla tion can be undertaken laparoscopi cally. 114 In a series of 252 patients undergoing laparoscopic RFA of 883 lesions, 118 (47%) developed local recurrence, with a local recurrence per lesion rate of 29%. 114 Ablation therapies can also be used as an adjunct to surgery; 111 for example, unilateral hemi-hepatectomy with ablation of lesions in the contralateral liver for patients with bilobar disease. 111 When used intraoperatively, the effectiveness of ablation is critically dependent on precise localization of the tumour using i ntraoperative ultrasonography. 61 Ablation therapy is not effective for larger liver lesions (>5 cm), and in tumour deposits adjacent to large vessels loss of thermal energy by conductive loss produces a heat-sink effect that compromises ablative efficacy. 111 Indeed, ablation therapy alone or in combination with resection is not recommended as a primary procedure for the treatment of liver metastases owing to these limitations and other restrictions related to tumour multiplicity, as well as the high local-failure rates associated with this technique. 111 Thus, although the preliminary evidence regarding ablation therapy is encouraging, no randomized trial data support the use of this technique in patients with CRC with synchronous liver-limited metastases, and use of this approach in clinical practice is typically decided on a case-by-case basis.
Overview of surgical outcomes
Outcome data in patients with CRC with synchronous hepatic metastases must be interpreted cautiously, bearing in mind that the criteria used to select patients with synchronous disease are not universally consistent, that the staging algorithms used vary between centres and over different time periods, and that wide hetero geneity exists in terms of treatment protocols and sequence of intervention. Early reports of simultaneous resection of the primary CRC and liver metastases predate the use of neoadjuvant chemotherapy and sophisticated staging protocols for detection of extra hepatic metastases. 115 For example, the feasibility of combining hepatic resection with bowel surgery requiring intesti nal anastomosis was reported in 1995. 116 In 1996, Nordlinger and colleagues 117 reported outcomes for 1,568 patients who underwent liver resection, 115 of whom were treated using synchronous bowel surgery. More recent data highlight important differences in morbidity (Table 1 ) and survival (Table 2 ) outcomes between series that evaluated patients who underwent either synchronous or staged resection; [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] however, clear trends have not emerged and, therefore, neither approach has been established as superior.
On the basis of the data presented in Table 2 , 14 inhospital mortality (accepting variations in definition) events were observed after the 838 synchronous bowel and liver resection procedures, suggesting a frequency of around 1.7%, although the in-hospital mortality rates recorded in the individual studies documented range from 0-10% (compared with 0-5% for classic staged bowel and liver resections). [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] Thus, these findings unequivocally establish that synchronous liver and bowel resection for the treatment of CRC with liver metastases is technically feasible in contemporary surgical practice. Assessment of the determinants of morbidity and disease outcome from these case-series is difficult as a result of the substantial variation in terminology and treatment protocols used between these studies. [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] Understanding of the optimal sequence of treatments in the setting of synchronous CRC and liver metastases is further complicated by reports detailing liverfirst surgery. For example, Broquet and colleagues 130 published outcomes in 156 consecutive patients with CRC and synchronous liver metastases treated at a single institution (the MD Anderson Cancer Center, Texas, USA) over a 16-year period up to 2009. The results of this investigation demonstrated the clinical evolution of synchronous and liver-first strategies over the course of the 21st century, but no marked differences in 5-year overall survival were observed between these approaches or the classic, bowel-first strategy. 130 Of note, however, the liver-first approach with neoadjuvant chemo therapy might lend itself as the firstline treatment. 17 Furthermore, in a small proportion of patients undergoing the liver-first strategy for treatment of rectal tumours with synchronous liver metastases, a complete clinical, endoscopic and radiological response to chemoradiotherapy subsequent to initial removal of the liver lesions enables a 'watchful waiting' approach to be adopted, thus delaying or even avoiding bowel surgery. 
Conclusions
The management of CRC with synchronous liver metastases is a common clinical challenge, and the approach taken is influenced by the clinical presentation of the disease. The involvement of modern multidisciplinary care teams is important in optimizing patient and disease management. 133 After adequate staging using contempor ary imaging techniques, treatment is logically based on the extent of disease and thus a range of different therapeutic strategies can be used in patients with CRC with systemic 'beyond-liver' metastases and those with liver-limited metastases (Figure 3) . The available evidence supports attempts aimed at downsizing of liver metastases using neoadjuvant chemotherapy in certain individuals with 'unresectable' liver metastatic disease that might become resectable, and modification of the future remnant liver to improve the post-hepatectomy functional capa city of the liver can also increase the number of patients eligible for liver resection.
Additional research is required to inform and optimize decision making regarding the options available for the management of CRC with liver metastases depending on the clinical status of individual patients. Important in this regard are further efforts to standardize the terminology and reporting used within the literature, which will facilitate comparison of data and thus better inform the treatment approaches. Key future advances in the treatment of CRC with synchronous liver metastases are likely to result from improved understanding of the cancer biology and the availability of targeted treatments aimed at disruption of cell proliferation pathways. In the current era, however, the goal of treatment for the majority of patients with CRC with synchronous liver-limited metastases is the surgical removal of the primary tumour and the hepatic lesions while integrating surgical care with chemo therapy in a manner designed to have optimum efficacy with minimum morbidity. 133 Patient preference, assessment and discussion of risks and options must remain central components to the delivery of complex care in an holistic individually-tailored manner. 
Review criteria
MEDLINE and EMBASE databases were searched for papers published between January 2000 and May 2013 using the following MeSH terms and key words: "colorectal neoplasms", "liver neoplasms" and "synchronous". Boolean operators were used to ensure that variations in key words were captured in searches. A separate search was performed using the Web of Knowledge (Version 5.5), including the science citation index, the social sciences citation index, the conference proceedings citation index and the Derwent innovations index, using "colorectal cancer", "synchronous liver metastases" and "surgery" as topics.
